A Prospective, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of a Cream Containing Xyloglucan, Pea Protein, and Opuntia Ficus-Indica Extract Versus Calcipotriol/Betamethasone in Adult Patients with Mild-to-Moderate Psoriasis.
March 2024
in “
PubMed
”
Studysummary This study found that an extract treatment showed similar efficacy and tolerability to calcipotriol/betamethasone ointment in reducing psoriasis severity and symptoms over 28 days in patients with mild-to-moderate plaque psoriasis.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study compared the efficacy and safety of a cream containing xyloglucan, pea protein, and Opuntia ficus-indica extract (XPO) to calcipotriol/betamethasone (CB) in adult patients with mild-to-moderate psoriasis. XPO demonstrated similar efficacy to CB in significantly reducing disease severity, erythema, itching, induration, and scaling. Additionally, XPO exhibited an excellent tolerability profile, suggesting it is a viable alternative treatment option for psoriasis.
